Table 2.
Growth hormone use, body composition and glucose tolerance in Turner syndrome.
| Parameter | Growth hormone (n = 76) | No growth hormone (n = 26) | p-value |
|---|---|---|---|
| Age (years) | 13.9 ± 3.6 | 13.6 ± 3.7 | NS |
| Height (SD) | −1.93 ± 0.8 | −2.51 ± 1.3 | 0.009* |
| BF (%) | 28.2 ± 8.3 | 35 ± 7.7 | <0.0001‡ |
| SAT (cm3) | 99.5 ± 81.8 | 183.2 ± 37.5 | 0.001‡ |
| VAT (cm3) | 33 ± 13.7 | 49.8 ± 7.8 | 0.0009‡ |
| IGT (%) | 7 | 28 | 0.006 |
Group means were compared by ANCOVA using:
*
Age.
‡
Age and BMI as covariates.
Prevalence of IGT was compared by χ2. Growth hormone was not administered the day before or day of metabolic testing. p-values remain significant at p < 0.01 after Bonferroni correction. Data are means ± standard deviation or proportion.
BF: Total body fat measured by dual energy X-ray absorptiometry; IGT: Impaired glucose tolerance; NS: Not significant; SAT: Subcutaneous abdominal fat;
SD: Standard deviation; VAT: Visceral abdominal fat.
Adapted from [2].